Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth

July 31, 2014 2:17 PM

Roth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.Ahead of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found